Status:
COMPLETED
Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction
Lead Sponsor:
National Institute of Cardiology, Warsaw, Poland
Conditions:
Acute Coronary Syndrome
Myocardial Infarction
Eligibility:
All Genders
18+ years
Brief Summary
This is the continuation of previous study (registration number: NCT00844987) which revealed that hepatocyte growth factor (HGF) is a very early, good marker of myocardial injury and prognostic factor...
Detailed Description
Hepatocyte growth factor (HGF) was examined in study number NCT00844987 as a potentially useful marker of acute myocardial injury. Results of the study confirmed efficacy of HGF as very early marker o...
Eligibility Criteria
Inclusion
- age \>18 years,
- chest pain,
- symptoms of ischemia at ECG,
- signed informed consent form
Exclusion
- age \< 18 years,
- not signed informed consent form.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01233336
Start Date
July 1 2010
End Date
December 1 2012
Last Update
February 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cardiology , CCU, ul. Alpejska 42
Warsaw, Poland, 04-628